I can certainly relate to number 3. Some years ago I worked for a biotech (no name disclosed but lets say its product was skin related in Melbourne). Funding was an ongoing issue. I remember that after one capital raising the CFO took all senior staff out to lunch and we were drinking $200 bottles of wine. Many staff commented that the business of the company seemed to be promoting its share price rather than the business of launching the product to market.
TIS Price at posting:
12.0¢ Sentiment: Hold Disclosure: Held